Maybe don't look at the price for a little while. There was a...

Maybe don't look at the price for a little while. There was a drop due to missed guidance. There are huge positives ahead, depending on your timeframe. If fluctuations in a not yet fully commercialised bio stock causes stress, high interest saving accounts are paying well right now. DYOR, but in my opinion we're likely to get the 250m sales milestone next Q, and meet with the FDA. And as posted by Kens recently, patients who had ceased are returning, new enrollments are picking up. It's still a high risk game but that is what comes with a young bio stock. Try and ignore the day-to-day and look forwards to September/October. I'm guessing JP takes little notice of the day-to-day and focuses on the big picture and long term value. That's what I'm trying to do. But yes, I know that's easier said then done.